First Command Financial Services Inc. Acquires 99 Shares of AbbVie Inc. (ABBV)

Marco Green
June 14, 2017

99 funds opened positions while 531 raised stakes.

The stock subtracted in the prior trading session by -0.2%, closing at the stock price of $69.53.

AbbVie Inc. (ABBV) has a market capitalization of 110.66 Billion which suggests the company is a huge company further suggesting that the shares of AbbVie Inc. Crossvault Mngmt Ltd Company holds 11,705 shares. The institutional investor owned 91,884 shares of the company's stock after selling 6,143 shares during the period.

In terms of AbbVie Inc. The dividend payment was $0.640 per share for the quarter or $2.56 annualized. British Columbia owns 728,715 shares or 0.4% of their U.S. portfolio. Partner Fund L P owns 1.17M shares. Andra Ap accumulated 37,900 shares.

Now have a look at past performance (weekly performance to year to date performance) how AbbVie Inc. Abbvie now has $112.12B valuation. 50,770 are held by Sigma Invest Counselors. Sumitomo Mitsui Asset Management Communication Limited invested 0.23% of its portfolio in AbbVie Inc (NYSE:ABBV).

Since February 28, 2017, it had 0 insider purchases, and 8 sales for $19.23 million activity. RICHMOND TIMOTHY J. sold 22,451 shares worth $1.47 million. Also, EVP Carlos Alban sold 43,000 shares of the business's stock in a transaction dated Thursday, May 4th. On Thursday, May 18 the insider CHASE WILLIAM J sold $2.50 million. GONZALEZ RICHARD A had sold 71,235 shares worth $4.67 million on Friday, May 19. After a recent check, AbbVie Inc (NYSE:ABBV)'s 14-day RSI is presently at 76.07. Michael Robert A. sold $335,068 worth of stock or 5,132 shares. About shares traded. AbbVie Inc (NYSE:ABBV) has risen 10.63% since June 13, 2016 and is uptrending. AbbVie Inc. has a 1-year low of $55.06 and a 1-year high of $70.03. Kayne Anderson Rudnick Mgmt Limited, a California-based fund reported 5,788 shares. The lower end of the projection is $1.36 per share, while the higher end is $1.42 per share. During the trading on 06/12/2017, Company's stock ranged from $69.83 to $68.72. It has underperformed by 6.07% the S&P500. It fall, as 86 investors sold ABBV shares while 555 reduced holdings. The company reported $1.28 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.26 by $0.02. "(ABBV)" was posted by Stock Observer and is the property of of Stock Observer. Next quarter's EPS is forecasted to be $1.40 and the next full year EPS is projected to be $6.48. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. Therefore 39% are positive.

11/28/2016 - AbbVie Inc. was downgraded to "neutral" by analysts at Citigroup. (ABBV) stock price comparison to its moving averages, shares of firm are 5.61% away from the 50-day moving average and 4.22% away from 20-day average. Harris had 18 analyst reports since August 10, 2015 according to SRatingsIntel. Goldman Sachs upgraded Harris Corporation (NYSE:HRS) on Tuesday, September 8 to "Buy" rating.

Investors of this firm earned a return of 9.50% on the assets it owns in past twelve month. The firm has "Overweight" rating by JP Morgan given on Monday, October 12. BidaskClub raised AbbVie from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Credit Suisse Group AG reaffirmed a "hold" rating and set a $65.00 target price on shares of AbbVie in a report on Wednesday. The company was initiated on Wednesday, July 22 by SunTrust. Raymond James initiated the stock with "Outperform" rating in Friday, September 2 report.

Among 18 analysts covering Abbvie Inc (NYSE:ABBV), 7 have Buy rating, 1 Sell and 10 Hold. As per Friday, October 23, the company rating was maintained by UBS.

More notable recent AbbVie Inc (NYSE:ABBV) news were published by: Seekingalpha.com which released: "Abbvie Vaults First Pivotal Hurdle With Oral RA Candidate" on June 09, 2017, also Bloomberg.com with their article: "AbbVie Testosterone Gel Faces Scrutiny as First Trial Begins" published on June 05, 2017, Seekingalpha.com published: "AbbVie: Too Risky" on May 17, 2017. First Command Financial Services Inc. boosted its position in shares of AbbVie by 6.8% in the first quarter.

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company.

The P/E ratio is now 18.02 and the market cap of the company is 110.66B.

The forward P/E ratio stands at 29.24. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER